UBC ELISA (Urinary Bladder Cancer)
The UBC ELISA is a one step in vitro diagnostic assay for the quantitative determination of cytokeratin 8 and 18 in urine. The assay is a sensitive indicator of tumor cell activity and is useful in the management of patients with urinary bladder cancer of epithelial origin.
Test Principle
UBC ELISA is a solid phase sandwich assay based on immunochemical technique. Standards, controls and samples react simultaneously with solid phase catcher antibodies (6D7 and 3F3) and the HRP conjugated detector antibody during incubation in the microstrip wells. After washing, the TMB substrate is added. Subsequently the reaction is stopped and the absorbance is read. The developed color is directly proportional to the concentration of the analyte.
Order Enquiry
References
- Stigbrand, T. et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: The ISOBM TD5-1 Workshop. Tumor Biol 1998; 19:132-152.
- Sánchez-Carbayo, M. et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, Cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001; 165:1462-1467.
- Giannopoulos, A. et al. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166:470-475.
Documents